If your child is squinting at the board, sitting closer to the TV, or getting a stronger glasses prescription every year, you are not alone. Childhood nearsightedness (myopia) is becoming more common, and it tends to get worse as kids grow. The encouraging news is that we now have proven ways to slow it down. This guide explains, in plain language, what the two main treatments actually do and how to think about which one fits your child.
At Mudgil Eye Associates in West Chester, our myopia management program is led by Dr. Reetu Julakanti, a residency-trained pediatric optometrist, as part of our pediatric eye care under Dr. A. Vijay Mudgil, a fellowship-trained pediatric ophthalmologist. We care for nearsighted children across Chester County and the Main Line.
Glasses or contacts fix blurry distance vision, but they do not stop the eye from continuing to grow longer, which is what drives nearsightedness in children. The goal of myopia management is different: to slow how fast the prescription climbs. That matters because higher levels of nearsightedness carry a greater lifelong risk of serious eye problems, including glaucoma, cataract, retinal detachment, and macular degeneration. The risk rises with the prescription, and children who end up around -6.00 diopters or higher, what is called high myopia, carry the most elevated lifetime risk. Keeping a child's myopia lower is an investment in their eye health for decades to come.
MiSight is a soft, daily-disposable contact lens that your child wears during the day. It does two jobs at once: it corrects their vision so they can see clearly without glasses, and its special design signals the eye to slow its growth. MiSight is FDA-approved specifically to slow the progression of myopia in children, the only contact lens with that approval. It tends to suit kids who are responsible enough to handle a daily lens (generally able to take it out themselves), and it is a great fit for active children and those who would rather not wear glasses. One limitation: MiSight does not correct significant astigmatism, so it is not right for every prescription.
The lens uses an optical design called ActivControl. It has two zones: a central zone that corrects distance vision, and a peripheral zone that creates a specific kind of blur toward the edges of the retina. That peripheral signal is what tells the eye to slow its growth.
It sounds counterintuitive that deliberately blurring part of the image would help, but the effect is well documented. In the pivotal three-year clinical trial, children wearing MiSight had 59 percent less myopia progression than children wearing standard contact lenses, and a seven-year extension study showed the benefit holding up across childhood. Because the lenses are daily disposables, they go in each morning and get thrown away at night, so there is no cleaning routine to keep up with.
Low-dose atropine is a single eye drop given once a night. A large body of international research shows it meaningfully slows myopia progression. It is simple for younger children and for kids who are not ready for contact lenses, and the child keeps wearing their regular glasses for clear vision. Atropine is very well tolerated, and side effects are uncommon. Two practical notes: for slowing myopia it is used off-label (it is not FDA-approved for this specific purpose, though it is widely used worldwide), and the low concentration has to be prepared by a compounding pharmacy rather than picked up at a standard pharmacy.
MiSight is FDA-approved for children ages 8 to 12 at the start of treatment, with nearsightedness between -0.75 and -4.00 diopters and minimal astigmatism. That range describes when treatment begins, not when it has to stop. Children who start inside that window keep wearing the lenses through their growing years, which is exactly what the seven-year data followed.
Outside that range there are still good options. For a child under 8, for one who is not ready to handle a contact lens, or for a prescription beyond the approved range, low-dose atropine is usually where we start. Whichever route fits, starting soon after myopia appears leaves the most progression left to prevent.
Both work. The better choice depends on your child's age, prescription, and comfort with contact lenses:
Some families start with one and switch later as the child grows. Dr. Julakanti reviews your child's eyes, prescription, and daily life and recommends the option most likely to help, then monitors progress at regular visits and adjusts as needed.
You may come across other options promoted online, such as orthokeratology (overnight "ortho-K" lenses), progressive bifocal glasses, and eye-exercise programs. The evidence behind these is more limited or mixed, and each comes with its own considerations. We tend to focus on the two approaches with the strongest research behind them, but we are always glad to talk through any option you have read about and whether it might be a good fit for your child.
The first visit is a comprehensive eye exam plus an axial length measurement, which tracks the actual physical growth of the eye rather than just the glasses prescription. We also talk through the lifestyle side, including screen time, outdoor time, and reading habits, and then build the plan with you.
After that, children come back a few months in and then about every six months for monitoring and lens supply. Most parents find these visits reassuring, because you can see on paper whether the progression is slowing.
Most medical insurance plans do not cover MiSight lenses or atropine drops, because they are treated as elective myopia control rather than treatment of an eye disease. We keep our self-pay rates transparent and give you a written estimate at the consultation. Some HSA and FSA accounts will cover the program.
Habits help alongside treatment. Encourage daily outdoor time, since children who get more natural daylight are less likely to become nearsighted. Make sure there is good lighting for reading and homework (reading in the dark is thought to worsen myopia), and build in regular breaks from screens and close work.
Most children in our program are between about 6 and 15 years old. Atropine is generally not used under age 5. MiSight is FDA-approved to start between ages 8 and 12, once a child can safely handle a contact lens. The earlier we start after myopia appears, the more progression we can prevent.
No. Neither treatment reverses myopia or eliminates the need for glasses. The goal is to slow how quickly the prescription gets worse, which protects long-term eye health.
Usually until the eyes stop growing and the prescription stabilizes, often into the early teen years or beyond. Children on atropine are typically treated for at least two years or until about age 15, whichever is longer.
Not significant astigmatism. MiSight is designed for children with minimal astigmatism, so if your child has a meaningful amount, we will look at atropine or another plan instead.
If your child's prescription keeps climbing, you have real options to slow it down. Learn more about our myopia management program, or read about myopia control for West Chester children. When you are ready, request a consultation with Mudgil Eye Associates, or call us at (610) 429-3004.
Medically reviewed by A. Vijay Mudgil, MD, board-certified, fellowship-trained pediatric ophthalmologist.
Have questions about your eye care? Our team at Mudgil Eye Associates would love to help.
Call 610-429-3004 or request your appointment online.
Learn more about our services: Cataract Surgery, Glaucoma, Pediatric Eye Care, Dropless Cataract Surgery, Premium IOLs, Cataract Surgery Cost.